Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

Nimodipine Capsules 30 mg Recalled by Caraco Pharmaceutical Laboratories Ltd. Due to Crystallization: Presence of crystals of Nimodipine within the...

Date: August 21, 2012
Company: Caraco Pharmaceutical Laboratories Ltd.
Status: Terminated
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Caraco Pharmaceutical Laboratories Ltd. directly.

Affected Products

Nimodipine Capsules 30 mg, Rx Only, For Institutional Use Only, a) 30-count unit dose Capsules (5x6 blister cards per carton), NDC 57664-135-64, b) 100-count unit dose Capsules (25x4 blister cards per carton), NDC 57664-135-65, Distributed by: Caraco Pharmaceutical Laboratories, Ltd. Detroit, MI 48202 Affiliate of Sun Pharmaceutical Industries, Inc.

Quantity: a) 2424 Cartons b) 2675 Cartons

Why Was This Recalled?

Crystallization: Presence of crystals of Nimodipine within the capsule solution.

Where Was This Sold?

One direct account - Caraco Pharmaceutical Labroatories, LTD Detroit, Michigan 78 sub accounts

About Caraco Pharmaceutical Laboratories Ltd.

Caraco Pharmaceutical Laboratories Ltd. has 2 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report